Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with or without irinotecan in KRAS wild-type or G13D metastatic colorectal cancer
2012-003638-18Phase 2Unknown
- Sponsor
- Australasian Gastro-Intestinal Trials Group, Sydney University
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing Cetuximab alone with Cetuximab plus irinotecan (2 arms). Primary endpoint: 6-month progression-free survival. Status: unknown.
02
Drugs
cetuximabirinotecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2012-003638-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003638-18.